Unger v. Amedisys Inc

CourtCourt of Appeals for the Fifth Circuit
DecidedFebruary 24, 2005
Docket03-30965
StatusPublished

This text of Unger v. Amedisys Inc (Unger v. Amedisys Inc) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Unger v. Amedisys Inc, (5th Cir. 2005).

Opinion

United States Court of Appeals Fifth Circuit F I L E D REVISED FEBRUARY 23, 2005 February 17, 2005 UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT Charles R. Fulbruge III Clerk _______________________

No. 03-30965 _______________________

FRANCES UNGER, ET AL.; Plaintiffs,

WILLIAM PATTERSON, lead plaintiff; GORDON ELLIS, lead plaintiff,

Plaintiffs-Appellees,

versus

AMEDISYS INC; ET AL.,

Defendants-Appellants.

Appeals from the United States District Court for the Middle District of Louisiana,

Before REAVLEY, JONES, and DENNIS, Circuit Judges.

EDITH H. JONES, Circuit Judge:

This case, on review pursuant to FED. RULE CIV. PROC. 23(f),

implicates the standards and procedures used by district courts

when considering certification of securities class actions

dependent on the “fraud on the market” theory. See Basic, Inc. v.

Levinson, 485 U.S. 224, 108 S. Ct. 978, 99 L. Ed. 2d 194 (1988).

Like our brethren in the Third, Fourth, Seventh and Ninth Circuits,

we hold that a careful certification inquiry is required and

findings must be made based on adequate admissible evidence to justify class certification. Because the district court

erroneously applied too lax a standard of proof to the plaintiffs’

fraud-on-the-market allegations, we must vacate the class certifi-

cation and remand.

BACKGROUND

Amedisys provides home health care, nursing, home infu-

sion therapy, and ambulatory surgery services. The company’s stock

is traded on the NASDAQ Over The Counter Bulletin Board (“OTCBB”).

Approximately ninety percent of Amedisys’s revenue comes from

Medicare. This case stems from the conduct of Amedisys and its

directors in reporting profits based on new Medicare procedures.

Beginning October 1, 2000, Medicare implemented the

Prospective Payment System (“PPS”), which altered the way Medicare

compensated home health care companies. Under PPS, Medicare paid

health care companies like Amedisys a portion of their fees in

advance, based on forward-looking estimates of the cost of

services. After the company provided the service, the remainder of

the fee was paid; alternatively, if the initial payment proved too

high, the company had to reimburse Medicare the difference. To

comply with the new PPS procedures, Amedisys purchased and

implemented new computer software.

Plaintiffs allege that Amedisys willfully manipulated the

PPS program to inflate the estimated costs for certain health

services; that it thereby artificially fueled company earnings;

2 and, ultimately, that Amedisys’s actions wrongfully enhanced its

stock price. On June 13, 2001, Amedisys issued a curative

statement, conceding that it had overstated revenues, but

maintaining that the overstatements were inadvertently caused by

the new software used with the PPS program. The stock price fell.

On August 21, 2001, Frances Unger filed suit against

Amedisys, alleging violations of Sections 10(b) and 20(a) of the

Securities Exchange Act of 1934 and Rule 10b-5 promulgated

thereunder. As is often the case, plaintiffs’ lawyers solicited

potential class members over the Internet and through newspaper

advertisements. Several other suits were consolidated with Unger’s

and five individuals were chosen as lead plaintiffs. Class

certification was requested for “all persons and entities who

purchased the common stock of Amedisys, Inc. between November 15,

2000 through [sic] June 13, 2001.” Discovery occurred to ascertain

the qualifications of the proposed class representatives. At a

hearing, the district court evaluated this evidence and the

plaintiffs’ sketchy evidence in support of the fraud-on-the-market

basis for their presumed reliance on Amedisys’s misrepresentations.

The district court certified the class under Rule 23(b)(3).

The Amedisys defendants timely sought, and this court

granted, an interlocutory appeal raising two issues embodied in the

class certification: the adequacy of the lead plaintiffs’ quali-

fications and the sufficiency of plaintiffs’ evidence to support

the fraud on the market presumption.

3 DISCUSSION

The class certification determination rests within the

sound discretion of the trial court. Gulf Oil Co. v. Bernard, 452

U.S. 89, 100, 101 S. Ct. 2193, 2200, 68 L. Ed.2d 693 (1981). That

discretion, however, must be exercised within the constraints of

Rule 23. Id. A district court that premises its legal analysis on

an erroneous understanding of the governing law has abused its

discretion. U.S. v. Insaulgarat, 378 F.3d 456, 464 (5th Cir.

2004); U.S. v. Mann, 161 F.3d 840, 860 (5th Cir. 1998).

Rule 23 requires the claims of a proposed class to meet

several requirements before the class can be certified. The party

seeking certification bears the burden of establishing that

all requirements of Rule 23 have been satisfied. Berger v. Compaq

Computer Corp., 257 F.3d 475, 479-80 (5th Cir. 2001). First, the

district court must find what has been termed numerosity,

commonality, typicality, and representativeness.1 For class

actions seeking money damages, like this one, the district court

must make additional findings of predominance and superiority.

Rule 23(b)(3). The predominance element requires a finding that

common issues of law or fact “predominate over any questions

1 The specific language of Rule 23(a) is: One or more members of a class may sue or be sued as representative parties on behalf of all only if (1) the class is so numerous that joinder of all members is impracticable, (2) there are questions of law or fact common to the class, (3) the claims or defenses of the representative parties are typical of the claims or defenses of the class, and (4) the representative parties will fairly and adequately protect the interests of the class.

4 affecting only individual members.” Id. This requirement,

although reminiscent of the commonality requirement of Rule 23(a),

is “far more demanding” because it “tests whether proposed classes

are sufficiently cohesive to warrant adjudication by

representation.” Amchem Prods., Inc. v. Windsor, 521 U.S. 591,

623-24, 117 S. Ct. 2231, 2249-50, 138 L. Ed. 2d 689 (1997). Final-

ly, a class action must afford the superior means to achieve “fair

and efficient adjudication of the controversy.” Rule 23(b)(3).

Recognizing the important due process concerns of both

plaintiffs and defendants inherent in the certification decision,

the Supreme Court requires district courts to conduct a rigorous

analysis of Rule 23 prerequisites. Gen’l Tel. Co. v. Falcon, 457

U.S. 147, 161, 102 S. Ct. 2364, 2372, 72 L. Ed. 2d 740 (1982).

District courts are required to take a “close look” at the parties’

claims and evidence in making its Rule 23 decision. Amchem, 521

U.S. at 615, 117 S. Ct. at 2246. Class certification hearings

should not be mini-trials on the merits of the class or individual

claims. Eisen v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Spence v. Glock Ges M B H
227 F.3d 308 (Fifth Circuit, 2000)
Stirman v. Exxon Corporation
280 F.3d 554 (Fifth Circuit, 2002)
Robinson v. Texas Automobile Dealers Ass'n
387 F.3d 416 (Fifth Circuit, 2004)
Eisen v. Carlisle & Jacquelin
417 U.S. 156 (Supreme Court, 1974)
University of Texas v. Camenisch
451 U.S. 390 (Supreme Court, 1981)
Gulf Oil Co. v. Bernard
452 U.S. 89 (Supreme Court, 1981)
General Telephone Co. of Southwest v. Falcon
457 U.S. 147 (Supreme Court, 1982)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Adrian Freeman v. Laventhol & Horwath
915 F.2d 193 (Sixth Circuit, 1990)
Hayes v. Gross
982 F.2d 104 (Third Circuit, 1992)
Robert Eckstein v. Balcor Film Investors
8 F.3d 1121 (Seventh Circuit, 1993)
Dianne Castano v. The American Tobacco Company
84 F.3d 734 (Fifth Circuit, 1996)
Margaret L. Johnston v. Hbo Film Management, Inc.
265 F.3d 178 (Third Circuit, 2001)
United States v. Luis Enrique Insaulgarat
378 F.3d 456 (Fifth Circuit, 2004)
Cammer v. Bloom
711 F. Supp. 1264 (D. New Jersey, 1989)

Cite This Page — Counsel Stack

Bluebook (online)
Unger v. Amedisys Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/unger-v-amedisys-inc-ca5-2005.